Canaccord Starts Titan Pharmaceuticals (TTP) at Buy
More News related to TTP
- Titan Pharmaceuticals (TTP) Announces Separation Agreements with CEO and COO; Company to Delist From AMEX
- Titan Pharmaceuticals (TTP) Announces 40% Reduction in Workforce
- Unusual 11 Mid-Day Movers 7/2: MAXY, APOL, ERII, NSTR Higher; MBRK, TTP, ALDN, DTG Lower
- Titan Pharmaceuticals (TTP) Announces Spheramine Presentation as AANS
- Canaccord Starts Titan Pharmaceuticals (TTP) at Buy
Canaccord Adams initaites coverage on Titan Pharmaceuticals (Amex: TTP) with a Buy rating and $4 price target.
The firm believes Titan should benefit from a "late-stage proprietary therapeutic pipeline of drugs for the treatment of central nervous system (CNS) disorders. Canaccord notes that the market for CNS treatment is attractive due to a high unmet medical need and above average growth. While this market is somewhat difficult to enter, Canaccord believes Titan "is pursuing a lower risk strategy coupled with strategic partnerships for two of its three late-stage assets."
Titan Pharmaceuticals, Inc., together with its subsidiaries, operates as a biopharmaceutical company that develops proprietary therapeutics for the treatment of central nervous system disorders, cardiovascular disease, bone disease, and other disorders. [BCS]
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
